Clinical Trial Insights In a Phase 2 clinical trial published in The New England Journal of Medicine , Retatrutide demonstrated remarkable efficacy: Participants with obesity (without diabetes) experienced up to 24.2% reduction in body weight over 48 weeks, surpassing results seen with existing medications
Dempsey reported that the GLP-1 agonist Zepbound removed the high intracranial pressure in one patient
Obesity Clinical Development Pipeline Muscle and Body Composition Other assets focused on preventing muscle loss in combination with incretin mimetics include Regenerons Phase 2 trevogrumab (myostatin) + garetosmab (ActA) combination, BioAges Phase 2 azelaprag (APJ), and Scholar Rocks Phase 2 apitegromab (myostatin)
More importantly, 81-97% of tirzepatide users achieved HbA1c below 7.0%the threshold for good diabetes control
Advanced / Aggressive Approach Note: Advanced dosing (1520 mg/day) is based on shortterm clinical trial protocols [4][5] for severe mitochondrial conditions and should only be pursued under medical supervision
Patients can use an inexpensive refrigerator thermometer to monitor temperature and ensure compliance with storage requirements